News

BioRestorative Therapies to Share Financial Insights Soon

BioRestorative Therapies to Share Financial Insights Soon

BioRestorative Therapies to Announce Financial Results

MELVILLE, N.Y. — BioRestorative Therapies, Inc. (“BioRestorative” or “BRTX”) (NASDAQ: BRTX), a pioneering innovator in regenerative medicine focused on stem cell-based therapies, is gearing up to release its financial results for the second quarter of 2025. This highly anticipated announcement is set to take place after the market closes on Tuesday, August 12, 2025. Following this release, the management team will be hosting a conference call to discuss the financial outcomes and provide an update on the company's business initiatives.

Details About the Conference Call

The specifics for the conference call are as follows:

Date and Time

The call is scheduled for Tuesday, August 12, 2025, at 4:30 p.m. Eastern Time.

Dial-In Information

Participants can join via the following numbers:

  • Domestic: 1-888-506-0062
  • International: 1-973-528-0011
  • Access Code: 436077

This call will provide an opportunity for participants to hear directly from BioRestorative's management, who will outline financial performance and business strategies moving forward.

Accessing the Call

The call will also be broadcast live and made available for archival listening on the Company’s website under the Investors section, specifically in the News & Events/IR Calendar area. This allows stakeholders and interested parties to stay in the loop about BioRestorative's developments.

About BioRestorative Therapies, Inc.

BioRestorative Therapies, located at www.biorestorative.com, is committed to developing unique therapeutic products that utilize cell and tissue protocols, with a strong focus on adult stem cells. The company is currently advancing two main clinical development programs that target spine and metabolic health:

Disc/Spine Program (brtxDISC™)

The company's flagship cell therapy product, BRTX-100, utilizes cultured mesenchymal stem cells sourced from the patient's own bone marrow. This innovative therapy is designed as a non-surgical option for managing painful lumbosacral disc disorders and can also be a complementary solution alongside surgical treatments. The production process for BRTX-100 is proprietary, involving the patient’s own cells to promote healing and recovery. A Phase 2 clinical trial is underway, focusing on chronic lower back pain linked to degenerative disc disease. Additionally, the company has secured FDA clearance to conduct trials evaluating the efficacy of BRTX-100 in treating chronic cervical disc pain.

Metabolic Program (ThermoStem)

BioRestorative is also delving into cellular therapies aimed at addressing obesity and metabolic conditions. This involves the use of brown adipose-derived stem cells to promote the development of brown adipose tissue. Early preclinical findings suggest that increasing brown fat could enhance calorie burning and improve glucose and lipid levels, potentially lowering diabetes and obesity risks. The insights being gathered here could significantly impact metabolic health solutions.

BioCosmeceuticals

In addition, the company is proud to offer a BioCosmeceutical platform featuring a cutting-edge product developed under cGMP standards in an ISO-7 certified environment. This serum, rich in exosomes, proteins, and growth factors, is specifically formulated to enhance cosmetic appearance by reducing fine lines and enhancing skin quality. BioRestorative aims to expand this segment, planning further IND-enabling studies to secure FDA approvals for a broader range of aesthetic applications.

Frequently Asked Questions

What date will BioRestorative announce its financial results?

BioRestorative will announce its financial results for the second quarter on August 12, 2025.

How can I join the conference call?

Participants can join the call by dialing 1-888-506-0062 for domestic calls and 1-973-528-0011 for international calls, using access code 436077.

What is the main focus of BioRestorative?

BioRestorative focuses on developing stem cell-based therapies and products aimed at addressing spine and metabolic health issues.

Where can I find more information about the company’s products?

More information can be found on BioRestorative's website, particularly in the Investors section.

What is the significance of BRTX-100?

BRTX-100 is BioRestorative's lead therapy aimed at treating chronic lower back pain through innovative regenerative techniques.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 307

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 107

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 311

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 281

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026

Updated Category News Views 597

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 296

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 188

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 179

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 0

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 471

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading

Top 5 Most Recently Viewed Articles

Midi Health and Mount Sinai Team Up for Menopause Care Access

Updated Category News Views 111

Midi Health and Mount Sinai Health System Join Forces Midi Health is excited to announce a new collaboration with Mount Sinai Health System, aimed at improving access to specialized menopause care for women in the New York City area. This partnership represents a crucial step in addressing the unmet needs of women experiencing perimenopausal and menopausal challenges. Why...

Continue Reading
Surety One, Inc.'s Charitable Matching Program Empowers Employees

Updated Category News Views 191

Surety One, Inc. Launches Charitable Matching Initiative Surety One, Inc. recently announced a noteworthy initiative: a corporate charitable matching program aimed at amplifying employee generosity. Through this program, the company will match employee donations to approved nonprofit organizations, offering a dollar-for-dollar match up to $2,500 per employee annually....

Continue Reading
Exploring Microsoft Stock's Seasonal Performance Before Earnings

Updated Category News Views 307

Could Now Be the Right Time to Invest in Microsoft? As Microsoft Corp. (NASDAQ: MSFT) prepares to unveil its fiscal first-quarter earnings soon, the question on the minds of many investors is whether now is an opportune moment to dive into this tech giant's stock. Data suggests a compelling case for this. Microsoft's Persuasive Seasonal Patterns Historically, the period...

Continue Reading
Foresight Technology VCT Reinforces Market Presence Through Buyback

Updated Category News Views 118

Strategic Share Buyback by Foresight Technology VCT PLC FORESIGHT TECHNOLOGY VCT PLC LEI: 21380013CXOR8N6OD977 The Board of Foresight Technology VCT plc has embarked on a strategic move to enhance its market dynamics. Recently, the Company executed a buyback, acquiring 35,274 of its FWT shares at a gross price of 87.88p each. This transaction occurred on the 24th of...

Continue Reading
Quarterhill's Virtual Annual Meeting Highlights Upcoming Changes

Updated Category News Views 157

Quarterhill's Virtual Annual Meeting Details Quarterhill Inc. is gearing up for its Annual and Special Meeting of shareholders, which will take place virtually. This exciting opportunity allows registered shareholders and proxyholders to participate actively by asking questions and voting in real time. They must follow the instructions mentioned in Quarterhill's...

Continue Reading